The New Zealand-owned company benefited from a lack of large claims and planned to hand back $45m of excess money not needed for payouts through a mandatory buy back of shares.

Its hospital products, which included humidification products used in respiratory, acute and surgical care, revenue was up 21 percent from a year ago.